The aim of the study was to assess the cellular proliferation in DLBCL in dogs based on the expression of TOPIIα and Ki-67 antigen, and to determine the MC value in terms of patient qualification for chemotherapy with anthracyclines. The gene discussed is TOP2A; the disease is diffuse large B-cell lymphoma.